Under Armour Over the Top

Recs

0

You have to hand it to the boys from Baltimore: They really outdid themselves on Wednesday.

Expected to produce profits of $0.07 per share, sportswear maker Under Armour (Nasdaq: UARM) actually turned in $0.18 per share worth of Q1 2006 earnings. Outstanding. Sales were up 51% year over year, net profits for the firm as a whole rose 248%, and profits per diluted share did even better, rising 260%.

So from a GAAP perspective, things went just swimmingly last quarter. But how'd the company do on cash profits? Unfortunately, that's pretty hard to say, because Under Armour didn't deign to provide its shareholders with a cash flow statement in its earnings release. Looking at the balance sheet, we see that cash levels declined between the end of December and the end of March, which suggests that free cash flow declined for the quarter. But we won't know for sure until the company files its Form 10-Q with the SEC, in which it is required to disclose its cash flows.

In the meantime, I'm going to go out on a limb -- part of the way, at least -- and say that free cash flow wasn't as strong as it should have been, even if it does turn out to have been positive. The reason hearkens back to the comments I made on Under Armour's working capital management in the earnings preview earlier this week. While sales have been strong, and inventory growth remarkably restrained, there's something funny going on over in the accounts receivable (A/R) department.

We can see on the company's balance sheet, which it did provide on Wednesday, that inventories again rose much more slowly (at 9%) than sales did. This suggests that demand for Under Armour's wares remains strong.

However, my concerns over A/R are actually growing stronger, not weaker. Year-over-year A/R growth in Q1 2006 was worse than we saw in either of the previous two quarters, with A/R rising more than twice as fast as sales: 103%. I'm not sure why that's happening, but it's worth noting that rapidly rising A/R have previously been associated with companies that are "channel stuffing" -- shipping goods out to retailers faster than they can be sold to consumers, in order to book the sales and create the appearance of a successful business. Past offenders have included Bristol-Myers Squibb (NYSE: BMY), Lucent (NYSE: LU), and possiblyTASER International (Nasdaq: TASR) and Harley-Davidson (NYSE: HDI) as well.

Is the same thing going on at Under Armour? I certainly hope not. But I've yet to hear a good explanation to the contrary.

TASER International is a Motley Fool Rule Breakers pick. Join David Gardner's quest for the next ultimate growth stock with a free 30-day guest pass.

Fool contributor Rich Smith does not own shares of any company named above.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 513194, ~/articles/articlehandler.aspx, 12/2/2008 4:47:10 AM,

Sign up for FREE Motley Fool site access to keep reading:

“Under Armour Over the Top”

Signing up allows you to comment on articles and on the discussion boards.

It's completely FREE and will take only 10 seconds.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

What Fools Are Saying

Most Recent

Most Recommended

Market Summary

S&P 500816.21 -8.93%
DJIA8,149.09 -7.70%
NASD1,398.07 -8.95%
Updated: 4:04:56 PM
Sponsored by:

Related Tickers

Bristol-Myers Squibb Co.

CAPS Rating 4/5 Stars

$19.36

-1.34 (-6.47%)

Outperform896

Underperform88

Rate This Stock